7 results on '"Juan M. Sarmiento"'
Search Results
2. Avoiding Pitfalls in Insulinomas by Preoperative Localization with a Dual Imaging Approach
- Author
-
Zachary L. Bercu, Juan M. Sarmiento, Collin J. Weber, Neil Saunders, Louis G. Martin, Kimberly M. Ramonell, Snehal G. Patel, and Jyotirmay Sharma
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Retrospective cohort study ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Dual imaging ,medicine.anatomical_structure ,Pancreatectomy ,Angiography ,medicine ,Radiology ,Tomography ,Pancreas ,business ,Insulinoma - Abstract
Insulinomas are rare endocrine malignancies of the pancreas that require surgical resection but can be difficult to localize preoperatively. We sought to review and improve the accuracy of preoperative localization techniques at our institution. We retrospectively reviewed all insulinomas that underwent resection at our institution between 1998 and 2016. Localization techniques include selective arterial calcium stimulation (CaStim), CT, MRI, angiography, and somatostatin receptor scintigraphy. Thirty-eight patients had pathologically proven insulinomas on surgical resection. Localization accuracies of CaStim, CT, and MRI were 89 per cent (31/35), 67 per cent (22/33), and 46 per cent (11/24), respectively. When compared with CTalone and CaStim alone, the combination of these two modalities resulted in 100 per cent preoperative localization (30/30), whereas the use of CaStim alone resulted in 80 per cent (4/5) localization and the use of CT alone resulted in 66 per cent (2/3) localization. Four of our patients had both negative CT and MRI. Among these patients, CaStim was 100 per cent localizing and the only positive modality for these patients. These data confirm that CaStim is accurate in preoperatively identifying single and multiple insulinomas; and when combined with CT, this accuracy is increased to 100 per cent. Based on these data, we propose that a dual imaging approach is a superior means of preoperative localization.
- Published
- 2019
3. Serous Cystadenoma of the Pancreas With Complex Florid Papillary Architecture: A Case Report and Review of the Literature
- Author
-
Juan M. Sarmiento, Yue Xue, Jessica Tracht, Aarti Sekhar, Erika Hissong, Michelle D. Reid, and Alyssa M. Krasinskas
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Benign Pancreatic Neoplasm ,Pancreaticoduodenectomy ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Gross examination ,Biopsy ,medicine ,Humans ,Pancreas ,Mural Nodule ,medicine.diagnostic_test ,business.industry ,Cystadenoma, Serous ,Nodule (medicine) ,Middle Aged ,Serous Cystadenoma ,Magnetic Resonance Imaging ,Cystic Neoplasm ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,medicine.anatomical_structure ,Surgery ,Anatomy ,medicine.symptom ,business - Abstract
Serous cystadenoma (SCA) is a relatively rare benign pancreatic neoplasm. It has a very distinctive gross and microscopic appearance including pure and mixed microcystic and macrocystic patterns as well as rare solid architectural pattern. In this article, we present a rare case of SCA with a complex florid papillary architecture. A 40-year-old man was diagnosed with a 3.5 cm SCA of the uncinate process of the pancreas based on abdominal computed tomography scan. The tumor was monitored radiographically until recent magnetic resonance imaging showed a new 1.0-cm eccentric mural nodule within the tumor with multiple arterial enhancing septations and features suspicious for a neuroendocrine tumor. A pylorus-preserving Whipple procedure was subsequently performed and the mass was resected. Gross examination confirmed the radiological findings of a well-demarcated, 3.5 cm multicystic pancreatic lesion with a 1.0 cm circumscribed, tan solid nodule at its periphery. Microscopic evaluation revealed a predominantly microcystic pattern classical of SCA with occasional macrocysts. The 1.0 cm discrete nodule was also a SCA, but showed unusually exuberant complex papillary growth. To our knowledge, this is the first reported case describing this morphologic variant. Recognition of this rare and unusual pattern is important to avoid misdiagnosis, especially on small biopsy specimens.
- Published
- 2019
4. Evaluation of Hemostatic Factors in Patients Undergoing Major Hepatic Resection and Other Major Abdominal Surgeries
- Author
-
Juan M. Sarmiento, Elliot B. Tapper, and Ken A. Tanaka
- Subjects
Prothrombin time ,medicine.medical_specialty ,Perioperative management ,medicine.diagnostic_test ,Hepatic resection ,business.industry ,General Medicine ,Perioperative ,Fibrinogen ,Gastroenterology ,Coagulation ,Internal medicine ,medicine ,In patient ,business ,Major hepatectomy ,circulatory and respiratory physiology ,medicine.drug - Abstract
The aim of this study was to evaluate the role for additional testing of coagulation in perioperative management of patients undergoing major hepatic resection. Major outcome measures were perioperative measurements of hemostatic factors (activated partial prothrombin time [aPTT], prothrombin time/international normalized ratio, fibrinogen, antithrombin-III). We conducted a prospective, single-blind study comparing hemostatic factors in patients undergoing major hepatectomy, Whipple procedures, and other gastrointestinal operations. Ninety-five consecutive patients were enrolled. No values differed significantly at baseline. Immediately postoperative, only international normalized ratio was significantly lower comparing major hepatectomy with Whipple ( P < 0.005) and other procedures ( P < 0.0032). Twenty-four hours postoperative, antithrombin-III was lower for major hepatectomy than Whipple ( P < 0.028) and others ( P < 0.0001); fibrinogen was lower compared with Whipple ( P < 0.014) and others ( P < 0.0009); international normalized ratio was lower to compared with Whipple ( P < 0.0001) and others ( P < 0.0001). aPTT measurements never differed significantly between groups at any time. Antithrombin-III and fibrinogen only correlated with international normalized ratio and aPTT for the other procedures. Additional hemostatic values beyond the standard evaluations of aPTT and international normalized ratio are needed to better assess patients undergoing major hepatic surgery.
- Published
- 2011
5. Risk Factors for Pancreatic Fistula after Stapled Gland Transection
- Author
-
Preeti Subhedar, Peter J. Kneuertz, Juan M. Sarmiento, Charles A. Staley, Shishir K. Maithel, Sameer H. Patel, David A. Kooby, and John R. Galloway
- Subjects
Univariate analysis ,medicine.medical_specialty ,business.industry ,Mortality rate ,General surgery ,Urology ,Retrospective cohort study ,General Medicine ,Odds ratio ,medicine.disease ,Confidence interval ,medicine.anatomical_structure ,Pancreatic fistula ,Diabetes mellitus ,medicine ,Pancreas ,business - Abstract
The objective of this study was to identify risk factors for pancreatic fistula (PF) after stapled transection in distal pancreatectomy (DP). Patients undergoing DP using a stapler for transection between 2005 and 2009 were identified from a pancreatic resection database. Variables examined included patient and tumor characteristics, staple size, and the use of mesh reinforcement. Univariate and multivariate regression analyses were performed to identify risk factors for postoperative PF. One hundred forty-nine had stapled transection, and of these, 25 (17%) had mesh reinforcement. The overall morbidity and mortality rates were 28 per cent and less than 1 per cent; 34 (23%) were diabetic. The rate of clinically significant PF was 14 per cent. On univariate analysis, diabetes ( P = 0.04), a firm pancreas ( P = 0.03), use of mesh staple line reinforcement ( P = 0.02), use of a 4.1-mm staple cartridge ( P = 0.01), and blood loss greater than 100 mL ( P = 0.01) were associated with higher pancreatic fistula rates. On multivariate analysis, only the presence of diabetes (OR, 4.17; 95% CI, 1.1-15.3; P = 0.03) and the use of a 4.1-mm cartridge (OR, 8.57; 95% CI, 1.2-60.2; P = 0.03) were independently associated with pancreatic fistula formation. Stapled pancreatic transection provides an acceptable PF rate after DP. Diabetes and staple size influence PF rates. In our experience, use of mesh staple line reinforcement did not reduce the incidence of PF after stapled transection.
- Published
- 2011
6. A Rare Nonmalignant Mass of the Pancreas: Case Report and Review of Pancreatic Sarcoidosis
- Author
-
Rabih Bechara, Martin Wijkstrom, and Juan M. Sarmiento
- Subjects
medicine.medical_specialty ,business.industry ,Concordance ,Autopsy ,General Medicine ,Disease ,medicine.disease ,Surgery ,Whipple Procedure ,medicine.anatomical_structure ,medicine ,Etiology ,In patient ,Radiology ,Sarcoidosis ,Pancreas ,business - Abstract
Sarcoidosis is a systemic granulomatous disease of unknown etiology affecting patients from all genetic backgrounds. Pancreatic involvement is rare; the first case was described on autopsy in 1937. We present a case of pancreatic sarcoidosis without a history of the disease presenting as biliary obstruction mimicking pancreatic malignancy. We also review the literature with respect to management and outcomes of similar cases. The patient described here presented with all the signs and symptoms of a pancreatic malignancy, which was confirmed on a CT scan; the positron emission tomography scan and the CA 19-9 level were also confirmatory of the suspected diagnosis. In this setting, if the mass looks resectable, a Whipple procedure would be the next logical step. However, such strategy would be aggressive management for a benign condition that could be palliated with diverting rather than resective procedures without changing the outlook of the disease. We suggest keeping a high index of suspicion in patients with a history of the disease if demographic concordance exists.
- Published
- 2010
7. Important Prognostic Factors in Adenocarcinoma of the Ampulla of Vater
- Author
-
Michael C. Lowe, Ipek Coban, David A. Kooby, Juan M. Sarmiento, Charles A. Staley, John R. Galloway, Carrie K. Chu, and N. Volkan Adsay
- Subjects
medicine.medical_specialty ,Lymphovascular invasion ,Proportional hazards model ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Ampulla of Vater ,Perineural invasion ,General Medicine ,Pancreaticoduodenectomy ,medicine.disease ,Malignancy ,Gastroenterology ,Surgery ,medicine.anatomical_structure ,Internal medicine ,medicine ,Adenocarcinoma ,business - Abstract
Ampullary adenocarcinoma (AmpCA) carries a better overall survival (OS) rate than other periampullary cancers. We examined clinicopathologic features in AmpCA for impact on OS. Records of patients undergoing pancreaticoduodenectomy from 2000 to 2007 for AmpCA were reviewed and histological specimens were reanalyzed. Of 302 patients undergoing pancreaticoduodenectomy for malignancy, 45 (14.9%) had AmpCA. Mean age was 61.3 ± 12.2 years, mean tumor size was 2.6 ± 1.3 cm, 57 per cent were ≥ T3 tumors, 42 per cent were N1 stage, 13 (49%) had perineural invasion (PNI), and 29 (64%) had lymphovascular invasion (LVI). Thirteen were intestinal (29%), 14 were pancreaticobiliary (31%), and 18 were mixed (40%). Median OS was 42 months (range 4-80 mos). On log rank testing, ≥ T3 (24 vs 65 mos, P < 0.01), N1 (25 vs 61 mos, P < 0.01), poor differentiation (24 vs 44 mos, P = 0.01), pancreaticobiliary subtype (23 vs 44 mos, P = 0.01), and PNI (23 vs 44 mos, P < 0.01) were significant for worse survival. By multivariate analysis, N1 disease (hazard ratio [HR] 4.50,95% confidence interval [CI] 1.16-17.40) and PNI (HR 4.62, CI 1.11-19.21) maintained associations with worse survival, whereas histological subtype did not. N1 disease and presence of PNI demonstrated independent associations with worse survival. Given high percentage of mixed histology, PNI may be more informative than the subtype in predicting outcome for patients with AmpCA.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.